NCT05678998View on ClinicalTrials.gov

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

October 18, 2024

Study Completion Date

February 5, 2025

Conditions
Advanced or Metastatic Solid TumorsNon-Hodgkin Lymphoma
Interventions
DRUG

WTX-330

Investigation Product

Trial Locations (9)

14203

Facility Name: Roswell Park Comprehensive Cancer Care, Buffalo

15232

University of Pittsburgh Medical Center, Pittsburgh

30322

Emory Winship Cancer Institute of Emory University, Atlanta

46202

Indiana University, Indianapolis

60611

Northwestern University, Chicago

78229

NEXT Oncology, San Antonio

85258

HonorHealth, Scottsdale

97213

Providence Cancer Institute Franz Clinic, Portland

02114

Mass General Hospital, Boston

All Listed Sponsors
lead

Werewolf Therapeutics, Inc.

INDUSTRY